Which Assumptions Drove a Psilocybin Cost-Effectiveness Model?
A decision model can show which assumptions most affect estimated costs. McCrone and colleagues used such a model to compare psilocybin-assisted therapy with medication, cognitive behavioral therapy, and their combination for severe depression.
What the model projected
The model simulated response, remission, and relapse over six months using inputs from earlier studies and estimates. It calculated expected costs and quality-adjusted life years, which combine duration and quality of life into one measure. Depending on the assumed drug price, projected healthcare costs for psilocybin-assisted therapy ranged from £6,132 to £7,652. These were model outputs rather than bills observed in a comparative trial.
Why support time and price mattered
Scenarios with lower drug prices and lower costs for therapist support made the intervention more favorable in the model. Reducing the assumed cost of support changes the calculation. It does not establish that delivering less support would produce equivalent clinical outcomes.
What would improve the estimate?
Observed delivery costs, direct evidence on different support arrangements, and longer-term outcome data would help test the assumptions. The six-month horizon leaves later relapse and longer-term service use outside the main calculation.
Study
McCrone P, Fisher H, Knight C, et al. Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychological Medicine. 2023;53:7619–7626. DOI 10.1017/S0033291723001411.



